RXRX — RECURSION PHARMACEUTICALS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-04-16.
Performance
Technicals
Others in Healthcare
Measured signals that fired on RXRX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-17 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-04 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-06 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-29 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-04 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-17 | Khan Najat CEO and President | Shares withheld for tax | 80.5K | 3.16 | 254.4K |
| 2026-08-17 | Hallett David Chief Scientific Officer | Shares withheld for tax | 26.7K | 3.16 | 84.2K |
| 2026-08-17 | Taylor Ben R Chief Financial Officer | Shares withheld for tax | 25.0K | 3.16 | 79.1K |
| 2026-08-04 | Borgeson Blake Director | Open-market sale 10b5-1 plan | 30.0K | 3.25 | 97.5K |
| 2026-07-07 | Borgeson Blake Director | Open-market sale 10b5-1 plan | 40.0K | 3.96 | 158.5K |
| 2026-07-01 | Li Dean Y Director | Grant or award | 3.7K | 0.00 | 0 |
| 2026-07-01 | Dar Zavain Director | Grant or award | 5.1K | 0.00 | 0 |
| 2026-06-18 | Bumpus Namandje Director | Open-market sale 10b5-1 plan | 4.0K | 3.18 | 12.6K |
| 2026-06-17 | Bumpus Namandje Director | Grant or award 10b5-1 plan | 88.4K | 0.00 | 0 |
| 2026-06-17 | Borgeson Blake Director | Grant or award | 88.4K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 132.6M | 43.2M |
| ARK Investment Management LLC | 123.5M | 40.2M |
| STATE STREET CORP | 87.5M | 28.5M |
| BAILLIE GIFFORD & CO | 72.7M | 23.7M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 69.9M | 22.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 68.3M | 22.2M |
| SOFTBANK GROUP CORP. | 41.9M | 13.6M |
| GEODE CAPITAL MANAGEMENT, LLC | 37.7M | 12.3M |
| MIC Capital Management UK LLP | 29.6M | 9.6M |
| GOLDMAN SACHS GROUP INC | 18.6M | 6.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about RXRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →